QR Code

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8–14 months, and there are few biomarkers and no cure available. It is hoped that, eventually, the incidence of MPM will drop and...

Full description

Saved in:
Main Authors: Fabio Nicolini, Martine Bocchini, Giuseppe Bronte, Angelo Delmonte, Massimo Guidoboni, Lucio Crinò, Massimiliano Mazza
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Oncology
Subjects:
malignant pleural mesothelioma (MPM)
immunotherapy
mesothelin
CAR (chimeric antigen receptor) T cells
miRNA replacement
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01519/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items